PolyPeptide follows an integrated approach to the management of environmental, social, and governance (ESG) topics that are considered material for its business. As a contract development and manufacturing organization (CDMO) serving pharma and biotech customers, PolyPeptide must adhere to stringent product quality requirements and regulations to protect the safety of patients. The Group seeks to promote corporate responsibility and to follow fundamental principles of business ethics and compliance to drive sustainable value creation for all stakeholders.
PolyPeptide believes that the integration of material ESG topics into its strategy, operations, and enterprise risk management framework is the most effective way to meet its business needs and stakeholder expectations. It uses a set of quantitative metrics to manage relevant ESG impacts, risks, and opportunities, and to track its impact and progress on sustainable development.
For further information regarding PolyPeptide’s strategy, market and business model, see Strategy – Polypeptide.
Find out more about PolyPeptide’s sustainability efforts in the Corporate Responsibility Report and Climate Report, published in the Annual Report 2024.
Our material ESG topics
PolyPeptide endorses the UN Agenda 2030 and considers the 17 SDGs as an important reference point for a sustainable future. In line with PolyPeptide’s six prioritized material topics below, the Group has set its sight to contribute to a number of relevant SDG goals.
Climate change mitigation
During 2024, PolyPeptide finalized its climate strategy and transition plan, including Greenhouse Gas (GHG) reduction targets which will be submitted for validation by the Science-Based Target initiative during 2025, The Climate Report includes the Group’s disclosure on climate-related matters in accordance with art. 946b CO.
People
PolyPeptide depends on its employees to run its operations in line with GMP requirements and to develop its project and technology portfolio, and its organization. The Group operates in compliance with EHS regulations and upholds strict principles for a fair, inclusive, and respectful workplace that values safety and work-life balance.
Green chemistry
PolyPeptide depends on its employees to run its operations in line with GMP requirements and to develop its project and technology portfolio, and its organization. The Group operates in compliance with EHS regulations and upholds strict principles for a fair, inclusive, and respectful workplace that values safety and work-life balance.
Product responsibility
PolyPeptide’s mission is to help its customers develop products, secure regulatory approvals, and successfully launch and commercialize their products. Through its network of six GMP-certified manufacturing sites on three continents, PolyPeptide strives to meet customer requirements in terms of quality, quantity, and time.
Supply chain engagement
PolyPeptide relies on an international network of suppliers for goods and services. The Group actively seeks to work with its suppliers to ensure and promote sustainable business and responsible human rights practices within its supply chain. It has a Group-wide Supply Chain Policy on Child Labor that reinforces its commitment to complying with all applicable laws and regulations on Child Labor.
Business ethics and compliance
PolyPeptide is committed to ethical behavior and compliance with legal and regulatory requirements. This includes a secure digital environment to protect sensitive data and business information. It requires adherence to its Code of Business Conduct and Ethics, with procedures in place to identify potential wrongdoing and misbehavior.
Our certifications and ratings
The Group participates in the Carbon Disclosure program (CDP), scoring a “B” rating in 2024, and improving for the third consecutive year versus the “B-” rating achieved in 2023 (2022: C). This is complemented by the EcoVadis ratings, where PolyPeptide received an “Advanced” rating for its carbon management program, in 2024 and a “Bronze” rating for its ESG program.
